Cardinal Health, Inc.
Cardinal Health, Inc. (CAH) Stock Competitors & Peer Comparison
See (CAH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CAH | $199.85 | -2.38% | 47B | 28.75 | $6.95 | +1.02% |
| MCK | $828.11 | -0.96% | 102.3B | 23.95 | $34.62 | +0.38% |
| COR | $308.19 | -1.03% | 59.9B | 36.94 | $8.34 | +0.75% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $77.54 | -0.87% | 8.9B | 23.71 | $3.27 | N/A |
| PBH | $58.94 | +2.03% | 2.8B | 15.55 | $3.79 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $37.57 | +1.62% | 2.4B | 48.15 | $0.78 | N/A |
| ACH | $3.30 | -1.79% | 251.5M | -2.46 | -$1.34 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
Stock Comparison
CAH vs MCK Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, MCK has a market cap of 102.3B. Regarding current trading prices, CAH is priced at $199.85, while MCK trades at $828.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas MCK's P/E ratio is 23.95. In terms of profitability, CAH's ROE is -0.59%, compared to MCK's ROE of -2.45%. Regarding short-term risk, CAH is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check MCK's competition here
CAH vs COR Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, COR has a market cap of 59.9B. Regarding current trading prices, CAH is priced at $199.85, while COR trades at $308.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas COR's P/E ratio is 36.94. In terms of profitability, CAH's ROE is -0.59%, compared to COR's ROE of +1.01%. Regarding short-term risk, CAH is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check COR's competition here
CAH vs ABC Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, CAH is priced at $199.85, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas ABC's P/E ratio is 21.92. In terms of profitability, CAH's ROE is -0.59%, compared to ABC's ROE of +1.01%. Regarding short-term risk, CAH is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check ABC's competition here
CAH vs HSIC Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, HSIC has a market cap of 8.9B. Regarding current trading prices, CAH is priced at $199.85, while HSIC trades at $77.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas HSIC's P/E ratio is 23.71. In terms of profitability, CAH's ROE is -0.59%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, CAH is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check HSIC's competition here
CAH vs PBH Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, PBH has a market cap of 2.8B. Regarding current trading prices, CAH is priced at $199.85, while PBH trades at $58.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas PBH's P/E ratio is 15.55. In terms of profitability, CAH's ROE is -0.59%, compared to PBH's ROE of +0.10%. Regarding short-term risk, CAH is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check PBH's competition here
CAH vs PDCO Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, CAH is priced at $199.85, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas PDCO's P/E ratio is 20.48. In terms of profitability, CAH's ROE is -0.59%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, CAH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check PDCO's competition here
CAH vs GRDN Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, CAH is priced at $199.85, while GRDN trades at $37.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas GRDN's P/E ratio is 48.15. In terms of profitability, CAH's ROE is -0.59%, compared to GRDN's ROE of +0.28%. Regarding short-term risk, CAH is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check GRDN's competition here
CAH vs ACH Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, ACH has a market cap of 251.5M. Regarding current trading prices, CAH is priced at $199.85, while ACH trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas ACH's P/E ratio is -2.46. In terms of profitability, CAH's ROE is -0.59%, compared to ACH's ROE of +7.33%. Regarding short-term risk, CAH is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check ACH's competition here
CAH vs OMI Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, CAH is priced at $199.85, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas OMI's P/E ratio is -0.47. In terms of profitability, CAH's ROE is -0.59%, compared to OMI's ROE of +7.33%. Regarding short-term risk, CAH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check OMI's competition here
CAH vs GEG Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, GEG has a market cap of 56.6M. Regarding current trading prices, CAH is priced at $199.85, while GEG trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas GEG's P/E ratio is -4.18. In terms of profitability, CAH's ROE is -0.59%, compared to GEG's ROE of -0.21%. Regarding short-term risk, CAH is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check GEG's competition here
CAH vs HX Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, CAH is priced at $199.85, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas HX's P/E ratio is -1.84. In terms of profitability, CAH's ROE is -0.59%, compared to HX's ROE of -1.07%. Regarding short-term risk, CAH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check HX's competition here
CAH vs WGRX Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, WGRX has a market cap of 9.2M. Regarding current trading prices, CAH is priced at $199.85, while WGRX trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas WGRX's P/E ratio is -0.09. In terms of profitability, CAH's ROE is -0.59%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, CAH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check WGRX's competition here
CAH vs SNYR Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, SNYR has a market cap of 3.9M. Regarding current trading prices, CAH is priced at $199.85, while SNYR trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas SNYR's P/E ratio is -0.31. In terms of profitability, CAH's ROE is -0.59%, compared to SNYR's ROE of +0.83%. Regarding short-term risk, CAH is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check SNYR's competition here
CAH vs ZYXI Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, CAH is priced at $199.85, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, CAH's ROE is -0.59%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, CAH is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check ZYXI's competition here
CAH vs MEHA Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, MEHA has a market cap of 743.8K. Regarding current trading prices, CAH is priced at $199.85, while MEHA trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas MEHA's P/E ratio is 10.80. In terms of profitability, CAH's ROE is -0.59%, compared to MEHA's ROE of +1.19%. Regarding short-term risk, CAH is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check MEHA's competition here
CAH vs RDGT Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, RDGT has a market cap of 478. Regarding current trading prices, CAH is priced at $199.85, while RDGT trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas RDGT's P/E ratio is -0.03. In terms of profitability, CAH's ROE is -0.59%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, CAH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.Check RDGT's competition here
CAH vs CVET Comparison April 2026
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 47B. In comparison, CVET has a market cap of 0. Regarding current trading prices, CAH is priced at $199.85, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 28.75, whereas CVET's P/E ratio is -69.97. In terms of profitability, CAH's ROE is -0.59%, compared to CVET's ROE of -0.06%. Regarding short-term risk, CAH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.Check CVET's competition here